

# CORhum - Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants

Head :LETAROUILLY Jean-Guillaume

Last update : 05/05/2021 | Version : 1 | ID : 73495

## General

### Identification

Detailed name Morbidity-mortality of COVID-19 in patients with chronic rheumatic disorder treated with immunosuppressants

Sign or acronym CORhum

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL 2021796 v 0, CPP CPP2020-06-056b, NCT04426279

### General Aspects

Medical area Internal medicine  
Rheumatology

Study in connection with Covid-19 Yes

Pathology (details) systemic lupus erythematosus, spondyloarthritis, rheumatoid arthritis

Keywords systemic lupus erythematosus, spondyloarthritis, chronic rheumatic disorder, biological therapy, rheumatoid arthritis, immunosuppressants

### Scientific investigator(s) (Contact)

Name of the director LETAROUILLY

Surname Jean-Guillaume

Address Service de Rhumatologie<br>Hôpital Roger Salengro<br>Rue Emile Laine<br>59037 Lille

Phone 320446926

Email jeanguillaume.letarouilly@chu-lille.fr

Organization Lille University Hospital

## Collaborations

Participation in projects, networks and consortia Yes

## Funding

### Governance of the database

Sponsor(s) or organisation(s) responsible Lille University Hospital

Organisation status Public

## Additional contact

## Main features

### Type of database

Type of database Study databases

Study databases (details) Not-repeated cross-sectional studies (except case control studies)

Database recruitment is carried out as part of an interventional study No

### Database objective

Main objective Estimate morbidity-mortality associated with COVID-19 in patients with chronic rheumatic disorder (CRD) receiving immunosuppressants (IS).

Inclusion criteria Patients with RA on csDMARD +/- bDMARD or tsDMARD +/- corticosteroid therapy fulfilling 2010 ACR/EULAR classification criteria? Patients with SpA receiving bDMARD or tsDMARD +/- csDMARD +/- non-steroidal anti-inflammatory drugs fulfilling ASAS classification criteria? Patients with SLE receiving hydroxychloroquine +/- csDMARD +/- corticosteroid therapy +/- bDMARD fulfilling 2019 ACR/EULAR classification criteria

### Population type

Age Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)

Population covered Sick population

Pathology L93 - Lupus erythematosus

M05-M14 - Inflammatory polyarthropathies

Gender Male  
Woman

Geography area Local

French regions covered by the database Nord - Pas-de-Calais Picardie

## Data collection

Dates

Size of the database

Size of the database (number of individuals) [500-1000[ individuals

Details of the number of individuals 1500

Data

Database activity Current data collection

Type of data collected Clinical data

Presence of a biobank No

Procedures

Followed pathology

## Promotion and access

Promotion

Access